The CompassHER2 Trial is a phase III, randomized study investigating the superiority of T-DM1 with versus without tucatinib in high-risk HER2+ BC patients who had pRD after neoadjuvant treatment with HER2–directed therapy [134]. Here, ERBB2 is linked to breast cancer.